Inflammation Marker and Fatty Liver Disease with Liver Scarring
Studies whether a blood inflammation ratio links to fatty liver disease and scarring.
Plain-language title generated from the registry record
Registry title: Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
Key facts
- Where
- Chongqing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at adults from the NHANES 2017-2020 survey who have metabolic dysfunction-associated fatty liver disease (MAFLD). It checks whether a blood inflammation marker relates to fat in the liver and liver scarring.
- Age
- 18 Years to 90 Years
- Sex
- All sexes can join.
- Disease stage
- Metabolic dysfunction-associated fatty liver disease (MAFLD): fat in the liver together with diabetes, overweight or obesity, or at least two metabolic risk abnormalities.
- Biomarker or test result
- The study looks at the ratio of high-sensitivity C-reactive protein to albumin (hsCAR).
Main reasons for not taking part
- No liver ultrasound data
- Incomplete clinical data
- Under 18 years old
- Cancer
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT05974904, who can take part
Where in China
- The Second Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaContact: Tingqiu Wang, BachelorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chongqing Medical University
- Trial code
- NCT05974904
- Record updated
- 12 February 2025
- Original description
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD).Read full original descriptionShow less
Association of High-sensitivity C-reactive Protein to Albumin Ratio with Metabolic Dysfunction-associated Fatty Liver Disease and Liver Fibrosis: a Cross-sectional Study
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD).
The main question[s] it aims to answer are:
[question 1] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? [question 2] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?
Inclusion: Total participants from NHANES 2017-2020; Participants diagnosed with MAFLD. Metabolic dysfunction-associated fatty liver disease (MAFLD) is the term used to describe hepatic steatosis in the presence of metabolic abnormalities, excess weight, obesity, or type 2 diabetic mellitus; Diagnosis of diabetes mellitus: (1) taking glucose-lowering drugs; (2) HbA1c ≥ 6.5% (48 mmol/mol); (3) fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL); (4) 2-hour plasma glucose (2hPG) ≥ 11.1 mmol/L (200 mg/dL); Overweight or obesity: defined as BMI≥25 kg/m2 in Caucasians or BMI≥23 kg/m2 in Asians; If presence of at least two metabolic risk abnormalities:; Waist circumference≥102/88 cm in Caucasian men and women (or≥90/80 cm in Asian men and women); Blood pressure≥130/85 mmHg or specific drug treatment; Plasma triglycerides≥150 mg/dl (≥1.70 mmol/L) or specific drug treatment; Plasma HDL-cholesterol <40 mg/dl (<1.0 mmol/L) for men and <50 mg/dl (<1.3 mmol/L) for women or specific drug treatment; Prediabetes (i.e., fasting glucose levels 100 to 125 mg/dl [5.6 to 6.9 mmol/L], or 2-hour post-load glucose levels 140 to 199 mg/dl [7.8 to 11.0 mmol] or HbA1c 5.7% to 6.4% [39 to 47 mmol/mol]); Homeostasis model assessment of insulin resistance score≥2.5; Plasma high-sensitivity C-reactive protein level >2 mg/L.
Exclusion: participants with cancer; participants under 18 years old; Liver ultrasound data not available; participants without complete clinical data.